Join
Live feed
·
PRReleasevia Quantisnow
Sonnet BioTherapeutics Holdings Inc. logo

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

ByQuantisnow·Wall Street's wire, on your screen.
SONN· Sonnet BioTherapeutics Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SONN (Sonnet BioTherapeutics Holdings Inc.) and more on Quantisnow.